The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.
Executives urge analysts to focus on the company's long-term potential.
Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.
Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.
The deal includes a $1.6-billion fee if AbbVie tries to walk away.